WST vs. ALGN, COO, XRAY, MMSI, HAE, QDEL, NEOG, ICUI, STAA, and ATRI
Should you be buying West Pharmaceutical Services stock or one of its competitors? The main competitors of West Pharmaceutical Services include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), QuidelOrtho (QDEL), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), and Atrion (ATRI). These companies are all part of the "health care supplies" industry.
Align Technology (NASDAQ:ALGN) and West Pharmaceutical Services (NYSE:WST) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
West Pharmaceutical Services has lower revenue, but higher earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
West Pharmaceutical Services has a net margin of 19.42% compared to West Pharmaceutical Services' net margin of 11.80%. Align Technology's return on equity of 20.57% beat West Pharmaceutical Services' return on equity.
In the previous week, Align Technology had 1 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 10 mentions for Align Technology and 9 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.24 beat Align Technology's score of 1.06 indicating that Align Technology is being referred to more favorably in the media.
Align Technology has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
Align Technology received 502 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 69.64% of users gave Align Technology an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
88.4% of Align Technology shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of Align Technology shares are owned by company insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Align Technology currently has a consensus price target of $353.00, suggesting a potential upside of 37.24%. West Pharmaceutical Services has a consensus price target of $435.20, suggesting a potential upside of 31.32%. Given West Pharmaceutical Services' higher probable upside, analysts clearly believe Align Technology is more favorable than West Pharmaceutical Services.
Summary
Align Technology and West Pharmaceutical Services tied by winning 9 of the 18 factors compared between the two stocks.
Get West Pharmaceutical Services News Delivered to You Automatically
Sign up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
West Pharmaceutical Services Competitors List
Related Companies and Tools
